QR code

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients

Prostate cancer (PCa) is the most common cancer in men worldwide. Despite better and more intensive treatment options in earlier disease stages, a large subset of patients still progress to metastatic castration-resistant PCa (mCRPC). Recently, poly-(ADP-ribose)-polymerase (PARP)-inhibitors have bee...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Alexander Giesen, Loïc Baekelandt, Wout Devlies, Gaëtan Devos, Herlinde Dumez, Wouter Everaerts, Frank Claessens, Steven Joniau
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2023-09-01
Reeks:Frontiers in Oncology
Onderwerpen:
prostate cancer
HRR genes
synergistic effect (combined treatment)
PARP inhibition (PARPi)
androgen receptor signaling inhibitor
Online toegang:https://www.frontiersin.org/articles/10.3389/fonc.2023.1265812/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items